



## Revisión

### Effects unrelated to anti-inflammation of lipid emulsions containing fish oil in parenteral nutrition for adult patients

*Efectos no relacionados con la antiinflamación de las emulsiones lipídicas que contienen aceite de pescado en la nutrición parenteral para pacientes adultos*

Javier Mateu-de-Antonio<sup>1</sup> and Marta Florit-Sureda<sup>2</sup>

<sup>1</sup>Pharmacy Department. Hospital del Mar. Barcelona, Spain. <sup>2</sup>Pharmacy Department. Corporació Sanitària Parc Taulí. Sabadell, Barcelona. Spain

### Abstract

Several reviews and meta-analyses on modulated inflammatory and immunologic responses after the administration of omega-3 polyunsaturated fatty acids (PUFAs) in different diseases and conditions have been published. However, omega-3 PUFAs exert several other actions which are not directly related to immunologic or inflammatory responses. The aim of this paper was to review the effects which are not directly related to immunologic and inflammatory responses of intravenous lipid emulsions (IVLEs) containing fish oil (FO) in parenteral nutrition (PN) for adult patients. IVLEs containing FO could have a role in the prevention of alterations in liver enzyme tests (LETs) or PN-associated liver disease (PNALD). Studies using FO doses of  $\geq 0.150$  mg/kg/day or IVLEs with high FO concentration reported more positive results than those with lower doses. Once PNALD was developed, the use of IVLEs exclusively composed of FO at doses of 0.25-1 g of FO/kg/day for several weeks could attenuate or even eradicate cholestasis and liver alteration. IVLEs containing FO seemed to have faster blood clearance, and this could be beneficial for some patients. Some studies also suggested a possible improvement of respiratory function by the administration of these IVLEs. In general, IVLEs containing FO were safe. Their use did not increase oxidative stress but, in contrast, increased plasma tocopherol content. They did not alter insulin sensitivity or glycemic control, and studies have found no relevant clinical effect on platelet aggregation or hemostasis. In conclusion, the use of IVLEs containing FO in PN may be beneficial with regard to older IVLEs, in addition to the modulation of systemic inflammation response.

#### Key words:

Fish oils. Intravenous fat emulsions. Parenteral nutrition. Omega-3 fatty acids.

### Resumen

Se han publicado varias revisiones y metaanálisis sobre la modulación de las respuestas inflamatorias e inmunológicas por la administración de ácidos grasos poliinsaturados (AGPI) omega-3. Sin embargo, los AGPI omega-3 ejercen otras acciones no directamente relacionadas con estas respuestas. El objetivo de este trabajo es revisar los efectos de las emulsiones lipídicas intravenosas (ELIV) que contienen aceite de pescado (AP) en la nutrición parenteral (NP) de pacientes adultos. Estas emulsiones pueden tener un papel importante en la prevención de las alteraciones del perfil hepático o de la enfermedad hepática asociada a la NP (EHANP) en comparación con las ELIV sin AP. Los estudios que usaron dosis  $\geq 0,150$  mg/kg/día presentaron resultados más positivos que aquellos con dosis menores. Una vez se ha presentado la EHANP, el uso de una ELIV compuesta exclusivamente de AP, a dosis de 0,25-1 g de AP/kg/día durante varias semanas, podría atenuar o incluso revertir la alteración hepática y la colestasis cuando la administración de la NP es crónica. Las ELIV con AP parecen tener un aclaramiento plasmático más rápido, lo que podría suponer una ventaja en ciertos pacientes. Algunos estudios también sugieren que estas emulsiones podrían mejorar la función respiratoria. En general, estas ELIV que contienen AP son muy seguras, no aumentan el estrés oxidativo e incluso incrementan el nivel de alfa-tocoferol plasmático. Asimismo, no alteran la sensibilidad a la insulina o el control glicémico y tampoco se ha demostrado que afecten clínicamente a la agregación plaquetaria o a la hemostasia. En conclusión, el uso de ELIV con AP en la NP podría suponer algunas ventajas frente a la ELIV sin AP, además de la modulación de la respuesta inflamatoria sistémica.

#### Palabras clave:

Aceites de pescado. Emulsiones lipídicas intravenosas. Nutrición parenteral. Ácidos grasos omega-3.

Received: 14/12/2016  
Accepted: 23/12/2016

Mateu-de-Antonio J, Florit-Sureda M. Effects unrelated to anti-inflammation of lipid emulsions containing fish oil in parenteral nutrition for adult patients. Nutr Hosp 2017;34:193-203  
DOI: <http://dx.doi.org/10.20960/nh.882>

#### Correspondence:

Javier Mateu-de-Antonio. Pharmacy Department.  
Hospital del Mar. Passeig Marítim, 25-29.  
08003 Barcelona, Spain  
e-mail: 92976@hospitaldelmar.net

## INTRODUCTION

In adult patients, the administration of omega-3 polyunsaturated fatty acids (PUFAs) from fish oil (FO) has been recommended to reduce inflammatory response. Several studies and reviews have been published on this topic in the last years. In a recent meta-analysis on patients with systemic inflammatory response syndrome, the addition of omega-3 PUFAs was associated with lower mortality and might have shortened the hospital length of stay (LOS). No differences between parenteral and enteral routes of administration regarding outcomes were found (1). In critically ill patients, the use of FO did not reduce mortality, but, on the contrary, it significantly diminished infectious complications and showed a tendency to reduce the days on mechanical ventilation and the LOS. Authors did not find differences in any endpoint amongst trials of parenteral and enteral nutritional strategies either (2). In pancreatitis, the use of omega-3 PUFAs has been shown to reduce mortality, infectious complications and LOS, especially when used parenterally (3).

These effects have been related to the immunomodulatory and anti-inflammatory action of omega-3 PUFAs. Their use, especially by parenteral route, diminishes several inflammatory biomarkers in both acutely and chronically ill patients (4). They also reduce interleukin-6, increase albumin and, additionally, decrease the C-reactive protein to albumin ratio in colorectal cancer patients (5).

However, omega-3 PUFAs from FO exert several other actions which are not directly related to immunologic and inflammatory responses. To our knowledge, these effects have not been reviewed in sum.

The aim of this paper was to review the effects which are not directly related to immunologic and inflammatory responses of intravenous lipid emulsions (IVLEs) containing FO as part of parenteral nutrition (PN) in adult patients. We divided these effects in potential benefits and possible concerns.

## POTENTIAL BENEFITS

### PREVENTION OF ALTERATIONS IN LIVER ENZYME TESTS (LETS) OR PARENTERAL NUTRITION-ASSOCIATED LIVER DISEASE (PNALD)

Several prospective studies have been published assessing the preventive effect of IVLEs containing FO on alterations in LETs or PNALD (6-21). Characteristics of these studies are shown in table I. Most of the studies were focused on middle-aged surgical or critically ill patients. Seven (44%) of the 16 studies found some positive results for LETs or liver ultrasound tests in patients receiving IVLEs containing FO (8,11,12,15,16,19,21). Studies using FO in doses of  $\geq 0.150$  mg/kg/day presented more positive results than those with lower doses. In five (63%) of the eight articles using doses  $\geq 0.150$  mg/kg/day some positive results in LETs were observed, whereas only two (25%) of the eight studies using

lower doses reported some positive results. This hypothesis could be reinforced by two recent retrospective studies. In a large retrospective study including more than 1,500 patients receiving PN, a higher FO dose was associated with a greater decrease in gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) in a multivariate adjusted model (22). Additionally, in a propensity score-matched study, a higher percentage of FO administered by PN was associated with lower LET elevation during PN (23).

In relation to the IVLE used, the most studied one is a multi-component oil emulsion containing soybean oil (SO) 30%, middle-chain triglycerides (MCT) 30%, olive oil (OO) 25%, and FO 15%. Four (50%) of the eight studies using this IVLE resulted in positive outcomes (8,11,16,21). The second most studied IVLE is an emulsion containing SO 40%, MCT 50%, and FO 10%. Two (40%) of the five studies with this IVLE rendered some positive results (15,19). Only one study tested an IVLE containing exclusively FO 100% administered in high doses, which lead to improved liver ultrasound test and better lactate dehydrogenase (LDH) in septic patients (12). Two additional studies tested a combination of an IVLE exclusively composed of FO 100% and an already marketed IVLE without FO. No differences in liver parameters were found (9,13).

These studies have several limitations regarding clinical practice. The first limitation is the length of the study period. PN lasted from four to eight days in most trials. This lapse could be shorter than the usual PN course in clinical settings. Only one study had a four-week duration, resulting in an improved LET using a multicomponent oil emulsion containing FO 15% in doses of  $> 0.150$  g/kg/day (16). Another important limitation is the age of the patients under assessment, who were younger than many patients requiring PN nowadays, usually older than 70.

In summary, IVLEs with FO in doses of FO  $> 0.150$  g/kg/day or with high proportion of FO could reduce the incidence of alterations in LETs or PNALD.

## TREATMENT OF PNALD

Treatment with IVLEs containing FO has not been thoroughly studied in adults after the development of PNALD. The first case was described by Jurewitsch et al. (24). A 75-year-old female required PN after a massive intestinal resection that led to short bowel syndrome. She developed hepatomegaly, altered LET, and an abnormal liver biopsy after ten weeks of PN containing an IVLE of SO 100%. After replacing the initial IVLE by an IVLE of FO 100%, in doses of 0.25 g FO/kg/day, liver span decreased, LET dropped, and liver biopsy normalized in approximately 20 weeks. To our knowledge, two additional cases have been described so far in patients requiring chronic PN (25,26). They developed severe liver alterations that could not be reversed except by replacing the initial IVLE (SO 100% and OO/SO 80%/20%, respectively) with an IVLE of FO 100%. The doses of FO used were about 1 g/kg/day.

Three studies focused on patients presenting LET alteration and PNALD. The first one is a retrospective study in 54 patients receiving long term PN that assessed the effect of adding taurine to PN on LET (27).

**Table I.** Prospective studies of IVLE containing FO on liver enzyme tests evolution or liver alteration

Ref.	Study	Patients' type	Patients analyzed	Mean age (years)	Control IVLE	FO dose (g/kg/day)	PN duration (days)	Energy supply (kcal/kg/day)	Results in experimental group in comparison to control group
<i>Experimental IVLE: SO/MCT/OO/FO 30%/30%/25%/15%</i>									
(21)	Prospective, double-blind, monocenter trial	Intensive care patients undergoing abdominal or thoracic surgery Postoperative period	20 (Experimental group: 10; control group: 10)	Experimental group: 70 Control group: 51	SO 100%	0.225	5	27.5	No direct comparison on liver function tests between groups Noticeably lower AST (48%), GGT (37%) and ALP (38%)
(6)	Prospective, randomized, controlled, double-blind, multicenter trial	Elective abdominal or thoracic surgery Postoperative period	199 (Experimental group: 99; control group: 100)	60	SO 100%	0.225	5	30-35	No differences in ASR, ALT, GGT, and ALP
(16)	Prospective, randomized, controlled, double-blind, multicenter trial	Stable intestinal failure requiring PN for at least four weeks Oral intake during the study allowed	73 (Experimental group: 34; control group: 39)	Experimental group: 53 Control group: 45	SO 100%	0.195	28	29	No differences in ALP and GGT About 35% lower AST and ALT values
(11)	Randomized, monocenter trial	Major abdominal surgery Postoperative period	41 (Experimental group: 15; control group: 26)	65	MCT/SO 50%/50%	0.210	4	31	No direct comparison on liver function tests between groups Noticeably lower bilirubin (40%) and GGT (33%)
(14)	Prospective, randomized, double-blind, monocenter trial	Abdominal surgery Postoperative period	40 (Experimental group: 20; control group: 20)	65	MCT/SO 50%/50%	0.150-0.300	5	30	No differences in bilirubin, AST, and ALT
(17)	Prospective, randomized, monocenter trial	Major abdominal surgery Postoperative period	40 (Experimental group: 20; control group: 20)	59	MCT/SO 50%/50%	0.125	5	30	No differences in bilirubin, AST, ALT, GGT, and ALP
(8)	Prospective, randomized, double-blind, monocenter trial	Major abdominal surgery or large cranio-maxillofacial resection Postoperative period	44 (Experimental group: 22; control group: 22)	70	OO/SO 80%/20%	0.15	5	25 as non-protein energy intake	About 40% lower AST, ALT, and alpha-glutathione S-transferase at second and fifth days

(Continuation in the next page)

**Table I (Cont.).** Prospective studies of IVLE containing FO on liver enzyme tests evolution or liver alteration

Ref.	Study	Patients' type	Patients analyzed	Mean age (years)	Control IVLE	FO dose (g/kg/day)	PN duration (days)	Energy supply (kcal/kg/day)	Results in experimental group in comparison to control group
(20)	Prospective, monocenter study	Abdominal surgery Postoperative period	154 (Experimental group: 78; control group: 76)	64	00/SO 80%/20%	Between 0.120- 0.150	7	Not reported	No differences in bilirubin, AST, ALT, GGT, and ALP
<i>Experimental IVLE: MCT/SO/FO 50%/40%/10%</i>									
(7)	Prospective, randomized, double-blind, multicenter trial	Major abdominal surgery Postoperative period	256 (Experimental group: 127; control group: 129)	59	MCT/SO 50%/50%	0.112 (Initially 0.070 for two days followed by 0.140 for three days)	5	Not reported	No differences in bilirubin, AST and GGT
(10)	Randomized, single-blind, monocenter trial	Critically ill patients with SIRS or sepsis	27 (Experimental group: 13; control group: 10)	Experimental group: 70 Control group: 57	MCT/SO 50%/50%	0.090	5	Experimental group: 29.3 Control group: 25.3	No differences in bilirubin, AST, ALT, and GGT
(15)	Prospective, randomized, monocenter trial	Major abdominal surgery Postoperative period	63 (Experimental group: 32; control group: 31)	55	MCT/SO 50%/50%	0.072 (Initially 0.040 for one day followed by 0.080 for four days)	5	25	No differences in AST, ALT, and GGT Total bilirubin decreased 15% while increasing 15% in the control group
(18)	Prospective, randomized, double-blind, multicenter trial	Critically ill patients EN during the study allowed	159 (Experimental group: 81; control group: 78)	60	MCT/SO 50%/50%	0.104	5	Around 23	No differences in the prevalence of cholestasis, liver necrosis, and mixed injury
(19)	Prospective, randomized, double-blind, monocenter trial	Major abdominal surgery Perioperative period	85 (Experimental group: 44; control group: 41)	62	MCT/SO 50%/50%	Between 0.080- 0.140	One preoperative day + seven postoperative days	20-35 (taking ideal body weight)	No differences in bilirubin, AST, and ALT A strong trend to lower increase in GGT
<i>Experimental IVLE: MCT/SO/FO 40%/40%/20%</i>									
(13)	Prospective, randomized, double-blind, monocenter trial	Surgical intensive care unit Postoperative period	30 (Experimental group: 18; control group: 12)	Mean not shown Range 19-74	MCT/SO 50%/50%	0.2 IVLE infused separately during 16 h/day	7	33	No differences in liver dysfunction, defined as twice the elevation of LET

(Continuation in the next page)

**Table I (Cont.).** Prospective studies of IVLE containing FO on liver enzyme tests evolution or liver alteration

Ref.	Study	Patients' type	Patients analyzed	Mean age (years)	Control IVLE	FO dose (g/kg/day)	PN duration (days)	Energy supply (kcal/kg/day)	Results in experimental group in comparison to control group
<i>Experimental IVLE: FO 10%</i>									
(12)	Randomized, placebo-controlled, monocenter trial	Critically ill patients diagnosed with systemic inflammatory response syndrome (SIRS) or sepsis	40 (SIRS: experimental group: 10; control group: 10) (Sepsis: experimental group: 10; control group: 10)	SIRS: experimental group: 62; control group: 54 Sepsis: experimental group: 44; control group: 69	SIRS: MCT/SO 50%/50% Sepsis: MCT/SO 50%/50%	0.600	7	Not shown	No differences in ALT, AST, and GGT LDH in control groups was twice that of experimental groups Sepsis control group had higher grades of fatty liver in ultrasound test
<i>Experimental IVLE: OO/SO/FO 67%/17%/16%</i>									
(9)	Prospective, randomized, double-blind, monocenter trial	Major abdominal surgery Postoperative period	37 (Experimental group: 13; control group: 14)	65	OO/SO 80%/20%	0.146	7	24	No differences in ALT, ALP, and GGT

PN: Parenteral nutrition; EN: Enteral nutrition; IVLE: Intravenous lipid emulsion; SO: Soybean oil; MCT: Middle-chain triglycerides; OO: Olive oil; FO: Fish oil; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; ASR: Albumin synthesis rate; ALT: Alanine aminotransferase; LET: Liver enzyme test; SIRS: Systemic inflammatory response syndrome.

Authors concluded that a synergistic effect could exist between taurine and a multicomponent IVLE of SO/MCT/OO/FO 30%/30%/25%/15% by reducing an altered LET. However, this effect was not accurately analyzed.

The second was an open-label study on 15 adults who developed cholestasis while receiving PN with IVLE of SO 100% (28). This treatment was partially replaced by an IVLE of FO 100% at doses of 0.15-0.2 g of FO/kg/day for at least one month. In this period, bilirubin and ALT dropped and liver biopsies showed a marked decrease in the degree of cholestasis and inflammation.

The last study focused on the effect of different IVLEs in ten adults with PNALD secondary to long-term PN. Additionally, an *in vitro* study assessed the effect of these IVLEs on human hepatocytes (29). The use of an IVLE of FO 100% at 1 g/kg/day for four months restored LET, fibrotic and inflammatory markers to normal values. This FO 100% emulsion showed not only a potent *in vitro* anti-inflammatory effect but also a possible direct antifibrotic effect in the liver.

As a concern, it has been hypothesized that the administration of IVLE with FO 100% as an exclusive source of fat does not provide the required essential fatty acid amount when used for

long periods (29). However, it has not been possible to prove this point clinically (25).

The substitution of the initial IVLE by one exclusively composed by FO or with high amounts of it and administered at doses of 0.25-1 g of FO/kg/day during several weeks could attenuate or even revert LET alterations or PNALD in patients under chronic PN.

## PLASMA LIPID CLEARANCE

Prospective studies collecting data on plasma clearance of IVLEs containing FO are presented in table II (6-8,12-14,16,17,19-21,30-34).

Three studies on healthy subjects assessed lipid oxidation or lipid plasma clearance specifically (31-33). These studies resulted in a 15-25% faster clearance or 25-45% shorter half-life of the experimental IVLE containing FO, although emulsions under assessment had different composition and FO content.

Thirteen clinical studies assessed clearance of IVLE with FO in hospitalized patients. Six of them (46%) reported higher clearance in the FO group as well (8,12,13,17,19,21).

Table II. Studies of IVLE containing fish oil

Ref.	Study type	Patients' type	Patients analyzed	Mean age (years)	Control IVLE	IVLE dose (g/kg/day)	FO dose (g/kg/day)	Energy supply (kcal/kg/day)	NP duration (days)	Results in experimental group in comparison to control group
<i>Experimental IVLE: SO/MCT/00/FO 30%/30%/25%/15</i>										
(21)	Prospective, double-blind, monocenter trial	Intensive care patients undergoing abdominal or thoracic surgery Postoperative period	20 (Experimental group: 10, control group: 10)	Experimental group: 70 Control group: 51	SO 100%	1.5	0.225	27.5	5	No direct comparison between groups Noticeably lower increase in triglyceridemia
(33)	Prospective, double-blind, crossover, randomized, controlled trial	Healthy male subjects	12	26	SO 100%	0.125 for 6 h	0.019	1.125 kcal/kg/h Only IVLE infused	--	Lower (42%) plasma triglyceride half-life No differences in plasma FFA, glycerol, and cholesterol
(6)	Prospective, double-blind, multicenter trial	Elective abdominal or thoracic surgery Postoperative period	199 (Experimental group: 99; control group: 100)	60	SO 100%	1.5	0.225	30-35	5	No differences in triglyceridemia and cholesterolemia
(8)	Prospective, randomized, double-blind, monocenter trial	Major abdominal surgery or large crano-maxillofacial resection Postoperative period	44 (Experimental group: 22; control group: 22)	70	00/SO 80%/20%	1	0.15	Non-protein energy intake 25 kcal/kg/day	5	Lower triglyceridemia at second day and at the end of the study (25%)
(14)	Prospective, randomized, double-blind, monocenter trial	Abdominal surgery Postoperative period	40 (Experimental group: 20; control group: 20)	65	MCT/SO 50%/50%	1 - 2	0.150-0.300	30	5	No differences in triglyceridemia, cholesterolemia, and HDL Lower (15%) LDL
(16)	Prospective, randomized, controlled, double-blind, multicenter trial	Stable intestinal failure requiring PN for at least four weeks Oral intake during the study allowed	73 (Experimental group: 34; control group: 39)	Experimental group: 53 Control group: 45	SO 100%	1.3	0.195	29	28	No differences in triglycerides Changes in plasma fatty acid pattern according to infused IVLE composition
(17)	Prospective, randomized, monocenter trial	Major abdominal surgery Postoperative period	40 (Experimental group: 20; control group: 20)	59	MCT/SO 50%/50%	0.833	0.125	30	5	Lower (25%) triglyceridemia at second day Lower increase (57%) of triglyceridemia at the end of the study

(Continuation in the next page)

Table II (Cont.). Studies of IVLE containing fish oil

Ref.	Study type	Patients' type	Patients analyzed	Mean age (years)	Control IVLE	IVLE dose (g/kg/day)	FO dose (g/kg/day)	Energy supply (kcal/kg/day)	NP duration (days)	Results in experimental group in comparison to control group
(20)	Prospective, monocenter study	Abdominal surgery Postoperative period	154 (Experimental group: 78; control group: 76)	64	00/SO 80%/20%	0.8-1	Between 0.120-0.150	Not reported	7	No differences in triglyceridemia, total cholesterol, HDL- and LDL-cholesterol
<i>Experimental IVLE: MCT/SO/FO 50%/40%/10%</i>										
(7)	Prospective, randomized, double-blind, multicenter trial	Major abdominal surgery Postoperative period	256 (Experimental group: 127; control group: 129)	59	MCT/SO 50%/50%	0.7 g/kg/day for two days followed by 1.4 g/kg/day for three days	0.112 g/kg/day (initially 0.070 g/kg/d for two days followed by 0.140 g/kg/d for three days)	Not reported	5	Higher triglyceridemia (40%), but in the normal range No differences in cholesterolemia
(31)	Prospective, crossover study	Healthy male subjects	8	23	MCT/SO 50%/50%	Variable to maintain stable hypertriglyceridemia close to 265 mg/dL (3 mmol/l)	Variable	Around 2.6 kcal/kg/h	4 (Study in a 5 h hypertriglyceridemic clamp)	Higher triglyceride clearance rate (17% or 24% depending on calculation applied)
(19)	Prospective, randomized, double-blind, monocenter trial	Major abdominal surgery Perioperative period	85 (Experimental group: 44; control group: 41)	62	MCT/SO 50%/50%	0.8-1	Between 0.080-0.140	20-35 kcal/kg ideal body weight/day	One preoperative day + seven postoperative days	Lower increase in triglyceridemia (65%) Greater decrease in FFA (85%) Lower decrease in HDL (17%)
<i>Experimental IVLE: MCT/SO/FO 40%/40%/20%</i>										
(13)	Prospective, randomized, double-blind, monocenter trial	Surgical intensive care unit Postoperative period	30 (Experimental group: 18; control group: 12)	Mean not shown Range 19-74	MCT/SO 50%/50%	One IVLE infused separately during 16 h/day	0.2	33	7	Lower triglyceridemia (approx. 25%) at fourth day and without differences at seventh day Both inside the normal range
<i>Experimental IVLE: MCT/FO 80%/20%</i>										
(32)	Prospective, double-blind, crossover, randomized, controlled trial	Healthy male subjects	12	29	MCT/SO 50%/50%	10 g IVLE in 5 min IV administration	2 g in 5 min IV administration,	-	Only IVLE administration	Triglyceride plasma half-life 25% shorter Plasma FFA peak and exposition 35% higher

(Continuation in the next page)

Table II (Cont.). Studies of IVLE containing fish oil

Ref.	Study type	Patients' type	Patients analyzed	Mean age (years)	Control IVLE	IVLE dose (g/kg/day)	FO dose (g/kg/day)	Energy supply (kcal/kg/day)	NP duration (days)	Results in experimental group in comparison to control group
<i>Experimental IVLE: FO 100%</i>										
(30)	Prospective, randomized, monocenter trial	Critically ill surgical patients	24 (Experimental group: 12; control group: 12)	56	SO 100%	0.25	0.25	21.7	5 (12 h metabolic study in the last day)	No differences in triglyceridemia, VLDL-triglycerides, free fatty acids, net lipid oxidation, and fractional hepatic <i>de novo</i> lipogenesis
(12)	Randomized, placebo-controlled, monocenter trial	Critically ill patients diagnosed with SIRS or sepsis	40 (SIRS: experimental group: 10; control group: 10) (Sepsis: experimental group: 10; control group: 10)	SIRS: experimental group: 62; control group: 54 Sepsis: experimental group: 44; control group: 69	SIRS: MCT/SO 50%/50% Sepsis: MCT/SO 50%/50%	0.6	0.600	Not shown	7	SIRS: lower triglyceridemia (30%) and LDL (50%) Sepsis: lower triglyceridemia (40%) and LDL (40%)
<i>Experimental: SO/FO 80%/20%</i>										
(34)	Prospective randomized double-blind, monocenter trial	Surgical intensive care unit Postoperative period	44 (Experimental group: 24; control group: 20)	61	SO 100%	0.96 (Initially 0.8 for one day followed by 1 for four days)	0.192 (Initially 0.16 for one day followed by 0.20 for four days)	24 (Initially 17.2 for one day followed by 25.8 for four days)	5	No differences in triglyceridemia, total cholesterolemia, and HDL-cholesterol Lower LDL-cholesterol and higher VLDL-cholesterol at third and fourth day

PN: Parenteral nutrition; IVLE: Intravenous lipid emulsion; SO: Soybean oil; MCT: Middle-chain triglycerides; OO: Olive oil; FO: Fish oil; HDL: High density lipoprotein; LDL: Low density lipoprotein; FFA: Free fatty acids; VLDL: Very low density lipoprotein; SIRS: Systemic inflammatory response syndrome.



Regarding the rest of clinical studies, six (46%) resulted in similar clearance to control emulsions (6,14,16,20,30,34), and only in one (8%) of them (7) triglyceridemia increased in the experimental group.

The most studied control IVLE was composed by MCT/SO 50%/50%. Seven (88%) of the eight studies which used this control resulted in faster lipid clearance of the IVLE containing FO. The remaining eight studies used control emulsions of SO 100% or OO/SO 80%/20%, three (38%) of them resulting in faster clearance for the IVLE containing FO.

A multicomponent IVLE containing SO 30%, MCT 30%, OO 25% and FO 15% has been recently used as a substitutive emulsion in patients who presented moderate hypertriglyceridemia (250-400 mg/dL) during PN containing an IVLE of OO/SO 80%/20%. This substitution resulted in a reduction in triglyceridemia of about 70 mg/dL (about 25%) and allowed maintaining the caloric intake, thus improving nutrition parameters without affecting the hepatic profile (35).

Taking all studies together, five (38%) out of 13 clinical studies and the three experimental studies resulted in faster clearance or shorter half-life in the IVLEs containing FO. The inclusion of FO in IVLEs could be beneficial to some patients as it improves lipid clearance.

## RESPIRATORY GAS INTERCHANGE

Few trials have investigated the effect of IVLEs with FO in gas exchange and the oxygenation index (ratio  $\text{PaO}_2/\text{FiO}_2$ ). In two studies respiratory function was improved, and a tendency to a shorter LOS during five days of PN in the group receiving an IVLE of MCT/SO/FO 50%/40%/10% in comparison to those being administered an IVLE of SO 100% (10,36) was observed. Doses of FO were 0.09 to 0.2 g/kg/day. Two more studies analyzed respiratory parameters in cardiac surgery patients. In one of them, 40 patients subject to elective coronary artery bypass grafting were randomized to receive a preoperative IVLE of FO 100% at doses of 10 g (about 0.11 g/kg) or saline. The results of this study showed that the extraction of oxygen and the uptake of lactate were markedly increased in the FO pretreated patients compared to the control group (37). In the second study, 23 patients were randomized to receive FO 100% 0.2 g/kg or saline administered two times on the evening before cardiopulmonary bypass and immediately before surgery. The FO group presented shorter ventilation time but no significant impact on the oxygenation index was observed (38).

On the other hand, no differences in relation to gas exchange parameters were found in a study on 16 patients with acute respiratory distress syndrome who were randomized in two different groups receiving IVLE containing either SO 100% or MCT/SO/FO 50%/40%/10%, administered at a dose of 0.12 g/kg/hour during 12 hours. The lack of beneficial results was attributed to the short duration of the treatment (39).

The mechanism by which FO could improve respiratory function was not clear (10).

## OTHER EFFECTS

In a randomized controlled clinical trial, patients who had undergone orthotopic liver transplantation and received PN with an IVLE of SO/MCT/FO 40%/40%/20%, at doses of FO 0.2 g/kg/day for seven days, presented better alanine aminotransferase (ALAT) profile and prognostic nutritional index, more reduced hepatic cell injury and higher prealbumin than patients receiving a similar PN without FO. In addition, the FO group had a decreased incidence of infectious complications and their post-transplant hospital stay was shorter (40). It has been hypothesized that IVLEs containing high amounts of FO are of benefit to patients who have undergone kidney transplantation and may require PN after severe complications (41).

In a single-arm phase II trial on patients with advanced pancreatic cancer, an IVLE containing FO (MCT/SO/FO 50%/40%/10%) was used to augment chemotherapy activity and improve quality of life. It was administered weekly as a standard intravenous infusion of 500 mL (FO 10 g) after the antitumor agent gemcitabine 1,000 mg/m<sup>2</sup> for three weeks, followed by a rest week. The study showed improved activity of the antitumor agent and improvement of the quality of life (42).

## POSSIBLE CONCERNS

### OXIDATIVE STRESS

FO contains a high percentage of long chain omega-3 PUFAs, such as eicosapentaenoic acid and docosahexaenoic acid, susceptible to oxidation that could increase oxidative stress. To counteract peroxidation reactions, IVLEs containing FO are enriched with higher doses of alpha-tocopherol, a lipophilic antioxidant (43).

Several studies have demonstrated that IVLEs partly or totally composed of FO increase plasma levels of alpha-tocopherol in comparison to IVLEs with SO 100% due to their high content of this vitamin (7,16,21,44,45). Doses used in these studies ranged from 0.7 to 2 g of fat/kg/day. Comparisons with other IVLEs without FO have not been made.

In addition, some studies assessed the effect of IVLEs with FO on oxygen radical production, peroxidation capacity or antioxidant capacity. No differences have been detected in oxidative status using IVLEs with FO in comparison to control IVLEs, mostly SO 100% (17,44-46). However, these studies used different techniques and oxidation markers, and had small samples and short time lipid administration. Thus, the use of IVLEs with high PUFA content did not seem to increase oxidative stress.

### INSULIN SENSITIVITY AND GLUCOSE METABOLISM

Elevated plasma free fatty acid levels are known to contribute to peripheral insulin resistance by impairing insulin-receptor signaling, which leads to decreased cellular glucose uptake and serum hy-

perglycemia, and can also reduce insulin secretion in subjects with impaired glucose tolerance (47). So far, three studies have examined glycemic control as a primary objective when administering IVLEs with FO. In the first study, 24 patients were randomized to receive an IVLE containing either FO 100% or SO 100%, in doses of 0.25 g of fat/kg/day, as part of PN for four days. No differences were detected in glucose metabolism in patients receiving FO (30). In the second study, 44 patients were randomized to receive PN containing an IVLE with SO 100% or an IVLE with SO/FO 80%/20% at doses of 1 g fat/kg/day for five days. Blood glucose levels normalized to the insulin doses applied and did not differ significantly between both groups. However, blood glucose levels fell significantly over time in the SO group, whereas they remained high in the SO/FO group (34). In the third study, 11 subjects with type 2 diabetes mellitus received infusions of SO 100% or SO/FO 89%/11% randomly by four-hour isoglycemic hyperinsulinemic clamps. Both IVLEs similarly decreased insulin-mediated glucose utilization. The IVLE with FO increased plasma free fatty acids. However, no difference regarding glucose utilization, insulin secretion and total energy production was observed between groups (46).

Two additional studies had glycemic control as a secondary outcome. In a randomized trial with 44 patients comparing a multicomponent emulsion of SO/MCT/OO/FO 30%/30%/25%/15% (FO dose 0.15 g/kg/day) *versus* OO/SO 80%/20% for five days, glucose levels and insulin dosage did not differ significantly between groups (8). Another study assessed 23 patients who were randomized to receive FO 100% 0.2 g/kg or saline administered twice on the evening before cardiopulmonary bypass and immediately before surgery. The average glycemia during the first 24 hours after surgery was significantly lower in the FO group. However, insulin requirements and endogenous glucose production were similar in both groups in the first 24 hours (38).

In a retrospective study, the substitution of an IVLE of SO/OO 80%/20% by a multicomponent IVLE containing SO/MCT/OO/FO 30%/30%/25%/15% in patients presenting moderate hypertriglyceridemia during PN resulted in a slight increase of insulin requirements, but it was attributed to the previous hypertriglyceridemia (35).

IVLEs with FO seemed not to alter significantly insulin sensitivity or glycemic control in clinical practice.

## HEMOSTASIS

Omega-3 PUFAs contained in FO have an antithrombotic effect mainly mediated by inhibiting cyclooxygenase, which transforms arachidonic acid into thromboxane A<sub>2</sub>, a platelet activator, and reducing its formation, thus leading to decreased platelet aggregation. Early studies raised concern about the safety of high doses of these lipids due to an increased risk of bleeding (48) that could not be proved later. However, this concern still persists nowadays.

Several studies assessed hemostasis parameters in patients receiving IVLEs with FO. In an early study mainly focused in hemostasis, 44 patients were randomly administered IVLEs with SO 100% or SO/FO 80%/20% in a dose of 1 g of fat/kg/day (FO 0.2 g/kg/day) for five days. However, no differences were found be-

tween groups in relation to thromboplastin time, activated partial thromboplastin time, fibrinogen, antithrombin III, factors VIIa and XIIa, and platelet function (49). In a more recent study already mentioned above, 40 patients undergoing coronary artery bypass graft surgery were randomized to receive either FO IVLE as single doses of FO 10 g (about 0.11 g/kg) 100% or saline solution before surgery and again four hours before starting extracorporeal circulation. The results showed no differences in international normalized ratio (INR), activated partial thromboplastin time, bleeding volume, blood transfusion or fresh frozen plasma requirements, platelet count in postoperative period, and heparin or protamine use. Only in one of four tests platelets activity was statistically lower in the FO group, but with no negative effect (50).

Three additional studies evaluated certain hemostasis parameters, but lacking a detailed analysis. They found no differences in INR (16), partial thrombin time (10), and prothrombin time (7). Two of them showed no differences in platelet counts (10,16), but a moderate difference regarding platelet count recovery after surgery was found in the FO group in the earliest study (7). FO doses ranged from 0.09 to 0.195 g/kg/day.

In general, studies have found no relevant clinical effect on platelet aggregation or hemostasis when administering IVLE with FO.

## CONCLUSIONS

The use of IVLEs containing FO in PN may have some advantages with respect to earlier IVLEs, not only in terms of modulation of systemic inflammation but in relation to further benefits. There are some evidences that IVLEs with FO may reduce the incidence of LET alterations during PN, eradicate PNALD, increase plasma lipid clearance, and improve respiratory gas exchange. Their use is safe, and possible concerns as alterations in oxidative stress, insulin sensitivity or hemostasis have not been confirmed so far.

## REFERENCES

1. Wan X, Gao X, Bi J, Tian F, Wang X. Use of n-3 PUFAs can decrease the mortality in patients with systemic inflammatory response syndrome: A systematic review and meta-analysis. *Lipids Health Dis* 2015;14:23.
2. Manzanares W, Langlois PL, Dhaliwal R, Lemieux M, Heyland DK. Intravenous fish oil lipid emulsions in critically ill patients: An updated systematic review and meta-analysis. *Crit Care* 2015;19:167.
3. Lei QC, Wang XY, Xia XF, Zheng HZ, Bi JC, Tian F, et al. The role of omega-3 fatty acids in acute pancreatitis: A meta-analysis of randomized controlled trials. *Nutrients* 2015;7(4):2261-73.
4. Rangel-Huerta OD, Aguilera CM, Mesa MD, Gil A. Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomarkers: A systematic review of randomised clinical trials. *Br J Nutr* 2012;107(Suppl 2):S159-70.
5. Mocellin MC, Camargo CQ, Nunes EA, Fiates GM, Trindade EB. A systematic review and meta-analysis of the n-3 polyunsaturated fatty acids effects on inflammatory markers in colorectal cancer. *Clin Nutr* 2016;35(2):359-69.
6. Mertes N, Grimm H, Furst P, Stehle P. Safety and efficacy of a new parenteral lipid emulsion (SMOFipid) in surgical patients: A randomized, double-blind, multicenter study. *Ann Nutr Metab* 2006;50(3):253-9.
7. Wichmann MW, Thul P, Czarnetzki HD, Morlion BJ, Kemen M, Jauch KW. Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541): Data from a prospective, randomized, multicenter trial. *Crit Care Med* 2007;35(3):700-6.

8. Piper SN, Schade I, Beschmann RB, Maleck WH, Boldt J, Rohm KD. Hepatocellular integrity after parenteral nutrition: Comparison of a fish-oil-containing lipid emulsion with an olive-soybean oil-based lipid emulsion. *Eur J Anaesthesiol* 2009;26(12):1076-82.
9. Badía-Tahull MB, Llop-Talaverón JM, Leiva-Badosa E, Biondo S, Farran-Teixidó L, Ramón-Torrell JM, et al. A randomised study on the clinical progress of high-risk elective major gastrointestinal surgery patients treated with olive oil-based parenteral nutrition with or without a fish oil supplement. *Br J Nutr* 2010;104(5):737-41.
10. Barbosa VM, Miles EA, Calhau C, Lafuente E, Calder PC. Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: A randomized, controlled clinical trial. *Crit Care* 2010;14(1):R5.
11. Hallay J, Olah AV, Fulesdi B, Kocsor M, Vegh T, Kovacs G, et al. Hepatobiliary response in postoperative lipid therapy in gastrointestinal surgery. *Hepatogastroenterology* 2010;57(102-3):1069-73.
12. Sungurtekin H, Degirmenci S, Sungurtekin U, Oguz BE, Sabir N, Kaptanoglu B. Comparison of the effects of different intravenous fat emulsions in patients with systemic inflammatory response syndrome and sepsis. *Nutr Clin Pract* 2011;26(6):665-71.
13. Han YY, Lai SL, Ko WJ, Chou CH, Lai HS. Effects of fish oil on inflammatory modulation in surgical intensive care unit patients. *Nutr Clin Pract* 2012;27(1):91-8.
14. Ma CJ, Sun LC, Chen FM, Lu CY, Shih YL, Tsai HL, et al. A double-blind randomized study comparing the efficacy and safety of a composite vs a conventional intravenous fat emulsion in postsurgical gastrointestinal tumor patients. *Nutr Clin Pract* 2012;27(3):410-5.
15. Wang J, Yu JC, Kang WM, Ma ZQ. Superiority of a fish oil-enriched emulsion to medium-chain triacylglycerols/long-chain triacylglycerols in gastrointestinal surgery patients: A randomized clinical trial. *Nutrition* 2012;28(6):623-9.
16. Klek S, Chambrier C, Singer P, Rubin M, Bowling T, Staun M, et al. Four-week parenteral nutrition using a third generation lipid emulsion (SMOFIpid): A double-blind, randomised, multicentre study in adults. *Clin Nutr* 2013;32(2):224-31.
17. Wu MH, Wang MY, Yang CY, Kuo ML, Lin MT. Randomized clinical trial of new intravenous lipid (SMOFIpid 20%) versus medium-chain triglycerides/long-chain triglycerides in adult patients undergoing gastrointestinal surgery. *J Parenter Enteral Nutr* 2014;38(7):800-8.
18. Grau-Carmona T, Bonet-Saris A, García-de-Lorenzo A, Sánchez-Álvarez C, Rodríguez-Pozo A, Acosta-Escribano J, et al. Influence of n-3 polyunsaturated fatty acids enriched lipid emulsions on nosocomial infections and clinical outcomes in critically ill patients: ICU lipids study. *Crit Care Med* 2015;43(1):31-9.
19. Ma CJ, Wu JM, Tsai HL, Huang CW, Lu CY, Sun LC, et al. Prospective double-blind randomized study on the efficacy and safety of an n-3 fatty acid enriched intravenous fat emulsion in postsurgical gastric and colorectal cancer patients. *Nutr J* 2015;14:9.
20. Martínez-Lozano F, Palacio P, Serrano JM, Caballero C, Gómez MJ, Sánchez C. Comparative study on the efficacy and safety of parenteral nutrition formulated with two different fat emulsions: SMOFIpid® compared with Clinoleic®. Preliminary study. *Nutr Hosp* 2016;33(3):515-21.
21. Antebi H, Mansoor O, Ferrier C, Tetegan M, Morvan C, Rangaraj J, et al. Liver function and plasma antioxidant status in intensive care unit patients requiring total parenteral nutrition: Comparison of 2 fat emulsions. *J Parenter Enteral Nutr* 2004;28(3):142-8.
22. Badía-Tahull MB, Llop-Talaverón J, Leiva-Badosa E. Impact of intravenous lipid emulsions on liver function tests: Contribution of parenteral fish oil. *Nutrition* 2015;31(9):1109-16.
23. Llop-Talaverón JM, Badía-Tahull MB, Leiva-Badosa E, Ramón-Torrell JM. Parenteral fish oil and liver function tests in hospitalized adult patients receiving parenteral nutrition: A propensity score-matched analysis. *Clin Nutr* 2016;5.
24. Jurewitsch B, Gardiner G, Naccarato M, Jeejeebhoy KN. Omega-3-enriched lipid emulsion for liver salvage in parenteral nutrition-induced cholestasis in the adult patient. *J Parenter Enteral Nutr* 2011;35(3):386-90.
25. Burns DL, Gill BM. Reversal of parenteral nutrition-associated liver disease with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition. *J Parenter Enteral Nutr* 2013;37(2):274-80.
26. Venecourt-Jackson E, Hill SJ, Walmsley RS. Successful treatment of parenteral nutrition-associated liver disease in an adult by use of a fish oil-based lipid source. *Nutrition* 2013;29(1):356-8.
27. González-Contreras J, Villalobos Gámez JL, Gómez-Sánchez AI, García-Almeida JM, Enguix Armanda A, Rius Díaz F, et al. Cholestasis induced by total parenteral nutrition: Effects of the addition of taurine (Tauramin®) on hepatic function parameters; possible synergistic action of structured lipids (SMOFIpid®). *Nutr Hosp* 2012;27(6):1900-7.
28. Xu Z, Li Y, Wang J, Wu B, Li J. Effect of omega-3 polyunsaturated fatty acids to reverse biopsy-proven parenteral nutrition-associated liver disease in adults. *Clin Nutr* 2012;31(2):217-23.
29. Pastor-Clerigues A, Marti-Bonmati E, Milara J, Almudever P, Cortijo J. Anti-inflammatory and anti-fibrotic profile of fish oil emulsions used in parenteral nutrition-associated liver disease. *PLoS One* 2014;9(12):e115404.
30. Tappy L, Berger MM, Schwarz JM, Schneiter P, Kim S, Revely JP, et al. Metabolic effects of parenteral nutrition enriched with n-3 polyunsaturated fatty acids in critically ill patients. *Clin Nutr* 2006;25(4):588-95.
31. Simoens CM, Deckelbaum RJ, Massaut JJ, Carpentier YA. Inclusion of 10% fish oil in mixed medium-chain triacylglycerol-long-chain triacylglycerol emulsions increases plasma triacylglycerol clearance and induces rapid eicosapentaenoic acid (20:5n-3) incorporation into blood cell phospholipids. *Am J Clin Nutr* 2008;88(2):282-8.
32. Carpentier YA, Hacquebard M, Portois L, Dupont IE, Deckelbaum RJ, Malaisse WJ. Rapid cellular enrichment of eicosapentaenoate after a single intravenous injection of a novel medium-chain triacylglycerol:fish-oil emulsion in humans. *Am J Clin Nutr* 2010;91(4):875-82.
33. Schlotzer E, Kanning U. Elimination and tolerance of a new parenteral lipid emulsion (SMOF): A double-blind cross-over study in healthy male volunteers. *Ann Nutr Metab* 2004;48(4):263-8.
34. Wendel M, Rössel T, Bergmann S, Otto S, Ragaller M, Zimmermann T, et al. Impact of total parenteral nutrition including omega-3 fatty acids on the regulation of plasma lipoproteins and glycemic control after major abdominal surgery. *e-SPEN* 2007;2(5):e103-e10.
35. Mateu-de Antonio J, Florit-Sureda M. New strategy to reduce hypertriglyceridemia during parenteral nutrition while maintaining energy intake. *J Parenter Enteral Nutr* 2016;40(5):705-12.
36. Wang X, Li W, Li N, Li J. Omega-3 fatty acids-supplemented parenteral nutrition decreases hyperinflammatory response and attenuates systemic disease sequelae in severe acute pancreatitis: A randomized and controlled study. *J Parenter Enteral Nutr* 2008;32(3):236-41.
37. Veljovic M, Popadic A, Vukic Z, Ilic R, Trifunovic Z, Antunovic M, et al. Myocardial protection during elective coronary artery bypasses grafting by pretreatment with omega-3 polyunsaturated fatty acids. *Vojnosanit Pregl* 2013;70(5):484-92.
38. Berger MM, Delodder F, Liaudet L, Tozzi P, Schlaepfer J, Chiolerio RL, et al. Three short perioperative infusions of n-3 PUFAs reduce systemic inflammation induced by cardiopulmonary bypass surgery: A randomized controlled trial. *Am J Clin Nutr* 2013;97(2):246-54.
39. Sabater J, Masclans JR, Sacanell J, Chacon P, Sabin P, Planas M. Effects on hemodynamics and gas exchange of omega-3 fatty acid-enriched lipid emulsion in acute respiratory distress syndrome (ARDS): A prospective, randomized, double-blind, parallel group study. *Lipids Health Dis* 2008;7:39.
40. Zhu X, Wu Y, Qiu Y, Jiang C, Ding Y. Effects of omega-3 fish oil lipid emulsion combined with parenteral nutrition on patients undergoing liver transplantation. *J Parenter Enteral Nutr* 2013;37(1):68-74.
41. Mateu-de Antonio J, Echeverría-Esnal D. Intravenous lipid emulsions in kidney transplant patients requiring parenteral nutrition. *Nutrition* 2016;32(3):397-8.
42. Arshad A, Isherwood J, Mann C, Cooke J, Pollard C, Runau F, et al. Intravenous omega-3 fatty acids plus gemcitabine: Potential to improve response and quality of life in advanced pancreatic cancer. *J Parenter Enteral Nutr* 2015.
43. Xu Z, Harvey KA, Pavlina TM, Zaloga GP, Siddiqui RA. Tocopherol and tocotrienol homologs in parenteral lipid emulsions. *Eur J Lipid Sci Technol* 2015;117(1):15-22.
44. Linseisen J, Hoffmann J, Lienhard S, Jauch KW, Wolfram G. Antioxidant status of surgical patients receiving TPN with an omega-3 fatty acid-containing lipid emulsion supplemented with alpha-tocopherol. *Clin Nutr* 2000;19(3):177-84.
45. Versleijen MW, Roelofs HM, Rombouts C, Hermans PW, Noakes PS, Calder PC, et al. Short-term infusion of a fish oil-based lipid emulsion modulates fatty acid status, but not immune function or (anti)oxidant balance: A randomized cross-over study. *Eur J Clin Invest* 2012;42(3):290-302.
46. Mostad IL, Bjerve KS, Basu S, Sutton P, Frayn KN, Grill V. Addition of n-3 fatty acids to a 4-hour lipid infusion does not affect insulin sensitivity, insulin secretion, or markers of oxidative stress in subjects with type 2 diabetes mellitus. *Metabolism* 2009;58(12):1753-61.
47. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. *J Clin Invest* 1999;103(2):253-9.
48. Lorenz R, Spengler U, Fischer S, Duhm J, Weber PC. Platelet function, thromboxane formation and blood pressure control during supplementation of the Western diet with cod liver oil. *Circulation* 1983;67(3):504-11.
49. Heller AR, Fischer S, Rossel T, Geiger S, Siebert G, Ragaller M, et al. Impact of n-3 fatty acid supplemented parenteral nutrition on haemostasis patterns after major abdominal surgery. *Br J Nutr* 2002;87(Suppl 1):S95-101.
50. Veljovic M, Mihajlovic I, Subota V, Antunovic M, Jevdjic J, Udovicic I, et al. Effect of pretreatment with omega-3 polyunsaturated fatty acids (PUFAs) on hematological parameters and platelets aggregation in patients during elective coronary artery bypass grafting. *Vojnosanit Pregl* 2013;70(4):396-402.